Feb 15th 2013 - Edison Investment Research today published a report on quickview entitled "Down, But Not Out". In summary, the report says:
Aveo has revealed final overall survival (OS) Phase III data for tivozanib in renal cell carcinoma (RCC), which shows a median OS of 28.8 months for tivozanib versus a median OS of 29.3 months with sorafenib in the control arm (p=0.105, HR=1.25). The OS trend in favour of the sorafenib arm is a clear concern with regard to tivozanib’s approvability by the FDA (PDUFA 28 July 2013), but the trial design may provide the mitigating circumstances to persuade the regulator that tivozanib has a role to play in RCC. A planned FDA advisory committee review of tivozanib in the coming months is therefore a major catalyst for the stock.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »